1. Prescription opioid misuse among middle-aged and older adults in the United States, 2015-2016.;Han;Prev Med,2019
2. Buprenorphine coverage in the Medicare Part D program for 2007 to 2018.;Hartung;JAMA,2019
3. The effect of formulary restrictions on patient and payer outcomes: a systematic literature review.;Park;J Manag Care Spec Pharm,2017
4. US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, MD, on the agency’s continued efforts to promote the safe adoption of medication-assisted treatment for opioid addiction. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-agencys-continued-efforts-promote-safe-adoption. Accessed April 4, 2019.
5. Centers for Medicare & Medicaid Services. Announcement of calendar year 2019 Medicare Advantage capitation rates and Medicare Advantage and Part D payment policies and final call letter. https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2019.pdf. Accessed April 4, 2019.